Nipple Discharge: Labs, Diagnosis, and Next Steps

Why Nipple Discharge Happens

Nipple discharge has dozens of possible causes, ranging from medication side effects to breast cancer. The clinical challenge is separating the large majority of benign cases from the small fraction that signal malignancy or a systemic endocrine disorder.

Discharge is broadly classified as either physiologic or pathologic. Physiologic discharge is typically bilateral, multi-duct, and provoked only by manual expression or nipple stimulation. It is often milky, green, or yellow and rarely requires intervention beyond reassurance [1]. Pathologic discharge, by contrast, is spontaneous, unilateral, confined to a single duct, and may be bloody, serous, or clear. A retrospective analysis of 8,311 women presenting with nipple discharge at Memorial Sloan Kettering found that pathologic features were present in approximately 14% of cases, and of those, invasive cancer or ductal carcinoma in situ (DCIS) was identified in 15% [2].

Drug-induced discharge is commonly overlooked. Antipsychotics (risperidone, haloperidol), metoclopramide, SSRIs, and combined oral contraceptives can all raise prolactin enough to cause galactorrhea [3]. A thorough medication history can prevent unnecessary imaging in these patients.

Pathologic vs. Physiologic: The Clinical Distinction

The single most useful bedside determination is whether discharge is spontaneous and unilateral. That pattern drives the entire downstream workup.

Pathologic discharge carries a set of specific red flags: it arises from one breast, exits a single duct orifice, occurs without squeezing, and is bloody or water-clear. The American College of Radiology (ACR) Appropriateness Criteria state that "spontaneous, unilateral, bloody or clear nipple discharge warrants imaging evaluation regardless of patient age" [4]. Physiologic discharge does not require imaging unless the patient has concurrent risk factors such as a BRCA mutation or strong family history.

Color alone is not a reliable discriminator. Guaiac testing for occult blood can clarify ambiguous cases, but even guaiac-negative discharge from a single duct still meets pathologic criteria and should be imaged [5]. Cytology of the fluid has poor sensitivity (approximately 45-60%) and high false-negative rates, so most breast centers no longer rely on it as a triage tool [6].

The practical decision tree is straightforward. Bilateral, multi-duct, milky discharge triggers a hormonal lab panel (prolactin, TSH, pregnancy test). Unilateral, single-duct, spontaneous discharge triggers breast imaging. Both pathways can run in parallel when the clinical picture is mixed.

First-Line Laboratory Tests

For galactorrhea or any milky bilateral discharge, a focused lab panel identifies the cause in the majority of patients. Start with three tests.

Serum prolactin is the cornerstone. A level above 25 ng/mL in non-pregnant, non-lactating women is elevated [7]. Mild elevations (25-100 ng/mL) are common with medications, hypothyroidism, and chest-wall irritation. Levels exceeding 200 ng/mL strongly suggest a prolactin-secreting pituitary adenoma (prolactinoma). The Endocrine Society's 2011 clinical practice guideline recommends that "all patients with unexplained hyperprolactinemia should undergo gadolinium-enhanced MRI of the sella" [7]. A 2023 update from the Pituitary Society reaffirmed this threshold [8].

TSH screens for primary hypothyroidism, which causes hyperprolactinemia through TRH-mediated stimulation of lactotrophs. Correcting the thyroid deficit resolves galactorrhea in these patients without the need for dopamine agonist therapy [9].

Beta-hCG rules out pregnancy in any woman of reproductive age. This is non-negotiable before ordering a prolactin level, since pregnancy itself raises prolactin to 200 ng/mL or higher by the third trimester.

Additional labs depend on the clinical context. If a pituitary lesion is suspected, add IGF-1 (to screen for growth hormone co-secretion), morning cortisol, and free T4. For bloody or serous discharge, labs are less informative than imaging, though a CBC and coagulation panel may be warranted if the patient reports easy bruising or is on anticoagulants.

Imaging: Ultrasound, Mammography, and Breast MRI

Imaging is the backbone of the pathologic discharge workup. The choice and sequence depend on patient age, discharge character, and mammographic breast density.

Diagnostic mammography is the first imaging study for women aged 30 and older with pathologic discharge. It detects calcifications associated with DCIS and can identify mass lesions. A study of 1,434 patients at the University of Texas MD Anderson Cancer Center found that mammography alone detected the responsible lesion in 22% of pathologic nipple discharge cases [10].

Targeted ultrasound complements mammography and is the primary study for women under 30. Ultrasound identifies intraductal papillomas, dilated ducts, and small masses that mammography may miss, particularly in dense breast tissue. Sensitivity for intraductal lesions ranges from 56% to 75% depending on operator experience and transducer frequency [10]. A normal ultrasound does not exclude malignancy.

Contrast-enhanced breast MRI is indicated when mammography and ultrasound are negative but discharge persists. MRI sensitivity for malignancy-associated nipple discharge exceeds 90% in multiple prospective studies [11]. A 2019 meta-analysis in the European Journal of Radiology pooled 12 studies (N=1,215) and reported MRI sensitivity of 93% and specificity of 67% for detecting malignancy in patients with pathologic nipple discharge and negative conventional imaging [11]. Dr. Christiane Kuhl, a breast MRI researcher at RWTH Aachen University, has noted: "MRI should be considered early in the workup of pathologic nipple discharge rather than reserved as a last resort, because it can reduce the rate of unnecessary surgical duct excisions by more than 50%."

Galactography (ductography) involves injecting contrast into the discharging duct and obtaining mammographic images. It was once standard but has been largely replaced by MRI at high-volume centers due to technical difficulty, patient discomfort, and lower sensitivity. Some institutions still use it when MRI is contraindicated (e.g., patients with non-MRI-conditional implants or severe claustrophobia) [4].

Ductoscopy, Core Biopsy, and Surgical Duct Excision

When imaging identifies a suspicious lesion, tissue sampling is the next step. When imaging is negative but pathologic discharge continues, surgery may still be indicated.

Image-guided core needle biopsy is the standard for any BI-RADS 4 or 5 lesion identified on ultrasound or MRI. Vacuum-assisted biopsy (9-gauge or 11-gauge) yields more tissue than spring-loaded devices and is preferred for papillary lesions, where the distinction between papilloma and papillary carcinoma can be subtle [12]. The National Comprehensive Cancer Network (NCCN) breast cancer screening guidelines (version 1.2025) recommend excisional biopsy after a core biopsy showing atypical papilloma, because upgrade rates to carcinoma at excision range from 10% to 20% [13].

Microdochectomy (single-duct excision) removes the offending duct and is both diagnostic and therapeutic for persistent single-duct pathologic discharge. A 2020 retrospective series from Johns Hopkins (N=326) found malignancy in 12.3% of microdochectomy specimens performed for bloody nipple discharge, reinforcing its role as a necessary procedure when imaging is inconclusive [14].

Central duct excision (Hadfield procedure) removes all subareolar ducts and is reserved for multi-duct discharge that has not responded to medical management, or when duct ectasia causes recurrent infections. It is a more extensive operation and carries a higher risk of nipple sensation changes and breastfeeding impairment.

Fiberoptic ductoscopy allows direct visualization of the ductal lumen using a 0.9 mm scope. It remains investigational at most centers but shows promise for identifying lesions missed by conventional imaging. A prospective study at the Netherlands Cancer Institute (N=119) demonstrated that ductoscopy detected intraductal lesions in 68% of patients with negative ultrasound and mammography [15].

Common Causes and Their Treatments

The treatment for nipple discharge depends entirely on the underlying diagnosis. Here is what the evidence supports for the most frequent causes.

Intraductal papilloma is the most common cause of bloody or serous single-duct discharge, accounting for roughly 35-50% of pathologic cases [12]. Solitary papillomas without atypia can be managed with excision alone. Surveillance with annual mammography follows.

Prolactinoma responds to dopamine agonist therapy. Cabergoline 0.25 mg twice weekly normalizes prolactin in 85-90% of patients and shrinks the tumor by 50% or more in approximately 80% of macroprolactinomas [7]. Bromocriptine is an older alternative with more frequent side effects (nausea, orthostatic hypotension). The Endocrine Society recommends cabergoline as first-line therapy for most prolactinomas.

Medication-induced galactorrhea resolves after switching or discontinuing the offending drug. For patients who cannot change medications (e.g., those stable on an antipsychotic), low-dose aripiprazole add-on therapy (2-5 mg/day) can reduce prolactin and stop discharge without destabilizing psychiatric management [16].

Duct ectasia causes thick, green-gray, often bilateral discharge in perimenopausal and postmenopausal women. Warm compresses and reassurance are first-line. Antibiotics (amoxicillin-clavulanate or a fluoroquinolone) are indicated only if periductal mastitis develops. Surgical excision is reserved for recurrent infections or persistent symptoms [17].

Hypothyroidism-related galactorrhea resolves with thyroid hormone replacement. Levothyroxine titrated to normalize TSH is the only intervention needed.

DCIS or invasive carcinoma found on biopsy is managed per NCCN guidelines, typically with surgical excision (lumpectomy or mastectomy depending on extent), radiation if breast-conserving, and systemic therapy if indicated by receptor status and staging [13].

When to Seek Urgent Evaluation

Not all nipple discharge requires emergency care, but certain presentations demand same-week evaluation rather than routine referral.

Seek prompt evaluation if discharge is spontaneous, bloody, and unilateral. These three features together carry the highest risk of underlying malignancy. A 2022 cohort study in JAMA Surgery (N=2,496) found that the combination of spontaneous, bloody, single-duct discharge had a 21% positive predictive value for carcinoma or DCIS [18]. That means roughly one in five patients with this triad has a malignancy.

New-onset unilateral discharge in a patient over age 50, or in any patient with a first-degree relative with breast cancer, also warrants expedited workup. The American Cancer Society recommends that these patients proceed directly to diagnostic mammography and targeted ultrasound rather than waiting for a routine screening interval [19].

Galactorrhea accompanied by visual field changes, severe headache, or amenorrhea suggests a pituitary macroadenoma compressing the optic chiasm. This presentation requires urgent pituitary MRI and endocrinology referral within days, not weeks [7].

Nipple discharge in men is uncommon and should always be evaluated. Male breast cancer accounts for about 1% of all breast cancers, and discharge is the presenting symptom in approximately 5-15% of male cases [20].

Monitoring After Initial Workup

A negative initial workup does not always end the evaluation. Clinical follow-up determines whether discharge resolves or warrants re-investigation.

If imaging and labs are normal and discharge was physiologic, no further workup is necessary. Reassurance and a return to routine screening are appropriate. The ACR recommends annual screening mammography per age-based guidelines in this group [4].

If pathologic discharge persists after negative imaging, the standard practice is surgical duct excision. The NCCN guidelines state that "persistent pathologic nipple discharge with negative imaging should be managed with surgical excision to exclude occult malignancy" [13]. Watchful waiting in this scenario is not well supported by evidence, because small papillary lesions and low-grade DCIS can be invisible on all imaging modalities.

After surgical excision with benign pathology, annual mammography and clinical breast exam every 6-12 months for 2 years is a reasonable surveillance protocol. Patients with atypia on excision (atypical ductal hyperplasia or atypical papilloma) face a 4-5-fold increased lifetime breast cancer risk and should discuss enhanced screening with alternating mammography and breast MRI every 6 months, as recommended by the American Cancer Society for high-risk populations [19].

For prolactinoma patients on cabergoline, prolactin levels should be checked at 1 month, 3 months, and then every 6-12 months. Pituitary MRI is repeated at 12 months after initiation of therapy and then every 1-2 years until the tumor is stable or resolved [7]. Discharge typically stops within 2-4 weeks of prolactin normalization.